Sugi Predict

Sugi Predict / Compounds / SCHEMBL19782696

SCHEMBL19782696

SCHEMBL19782696

COc1cc(Br)c(N)c(C=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKDC P78527 1/20 0.48
▸ ERN1 O75460 4/20 0.46
▸ ALDH1A1 P00352 8/20 0.43
▸ TRIM24 O15164 1/20 0.42
▸ TYR P14679 1/20 0.42
▸ TRIM33 Q9UPN9 1/20 0.42
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40
▸ TUBB3 Q13509 1/20 0.40
▸ TUBB2A Q13885 1/20 0.40
▸ TUBB8 Q3ZCM7 1/20 0.40
▸ TUBA3E Q6PEY2 1/20 0.40
▸ TUBA1A Q71U36 1/20 0.40
▸ TUBA1C Q9BQE3 1/20 0.40
▸ TUBB6 Q9BUF5 1/20 0.40
▸ TUBB2B Q9BVA1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31274281 0.81 TUBB4A (0.60) PRKDCERN1ALDH1A1TRIM24TYR
SCHEMBL24447268 0.81 TUBB4A (0.40) PRKDCERN1ALDH1A1TUBB4ATUBB
SCHEMBL6828189 0.79 ERN1 (0.52) PRKDCERN1ALDH1A1TRIM24TYR
SCHEMBL23796052 0.79 GAA (0.36) PRKDCERN1ALDH1A1LMNACYP1A2
SCHEMBL666672 0.79 ALDH1A1 (0.53) ALDH1A1KDM4ETDP1MAPTNPSR1
SCHEMBL1119262 0.78 PRKDC (0.50) PRKDCERN1ALDH1A1TRIM24TYR
SCHEMBL23796305 0.78 POLB (0.42) PRKDCERN1MAPTLMNAPOLB
SCHEMBL931983 0.77 ERN1 (0.60) PRKDCERN1ALDH1A1TRIM24TYR
SCHEMBL28607913 0.77 PRKDC (0.48) PRKDCERN1ALDH1A1TRIM24TYR
SCHEMBL5649939 0.76 ERN1 (0.48) PRKDCERN1ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223306-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIOVENTURES, INC., 2025-07-10 — — US disclosed
CN-119522215-A TEAD inhibitors and methods of use 思博睿生物探索公司 2025-02-25 — — CN disclosed
EP-4496789-A1 TEAD INHIBITORS AND METHODS OF USE Sporos Biodiscovery, Inc. (US) 2025-01-29 — — EP disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
EP-4358948-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-05-01 — — EP disclosed
US-11866431-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-01-09 — — US disclosed
WO-2023183437-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIODISCOVERY, INC. (US) 2023-09-28 — — WO disclosed
WO-2023183437-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIODISCOVERY, INC. (US) 2023-09-28 — — WO disclosed
US-20230061429-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230053649-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. 2023-02-23 — — US disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 — — CN disclosed
WO-2022272036-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 — — WO disclosed
EP-3877356-A1 BICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-09-15 — — EP disclosed
CN-113302175-A Bicyclic compounds 维瓦斯治疗公司 2021-08-24 — — CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 — — EP disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 — — US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 — — US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866431-B2 Bicyclic compounds YAP1, MYC, TEAD2 PRKDC 2352/4885ERN1 2816/4885ALDH1A1 2731/4885
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 PRKDC 2594/4885ERN1 4020/4885ALDH1A1 1598/4885
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 PRKDC 3204/4885ERN1 4029/4885ALDH1A1 1618/4885
US-20250223306-A1 TEAD INHIBITORS AND METHODS OF USE TEAD1, TEAD2, TEAD3 PRKDC 140/4885ERN1 2147/4885ALDH1A1 1945/4885
US-20230061429-A1 BICYCLIC COMPOUNDS YAP1, MYC, TEAD2 PRKDC 2352/4885ERN1 2816/4885ALDH1A1 2731/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 PRKDC 2594/4885ERN1 4020/4885ALDH1A1 1598/4885
US-20230053649-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 PRKDC 74/4885ERN1 3628/4885ALDH1A1 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.